PTCT - PTC Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
46.31
+0.94 (+2.07%)
At close: 4:00PM EDT

46.31 0.00 (0.00%)
After hours: 4:27PM EDT

Stock chart is not supported by your current browser
Previous Close45.37
Open45.39
Bid42.00 x 1200
Ask49.87 x 800
Day's Range45.36 - 46.68
52 Week Range14.56 - 52.95
Volume824,761
Avg. Volume1,015,898
Market Cap2.328B
Beta2.64
PE Ratio (TTM)N/A
EPS (TTM)-1.40
Earnings DateOct 31, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.17
Trade prices are not sourced from all markets
  • How’s PTC Therapeutics Positioned in September?
    Market Realist6 days ago

    How’s PTC Therapeutics Positioned in September?

    In the second quarter, PTC Therapeutics generated revenues of $68.7 million—compared to $48.0 million in the second quarter of 2017, which reflected ~43% growth YoY (year-over-year). In the first half of 2018, PTC Therapeutics reported net revenues of $124.8 million—compared to $74.5 million in the first half of 2017.

  • Analyzing PTC Therapeutics’ Performance in September
    Market Realist6 days ago

    Analyzing PTC Therapeutics’ Performance in September

    On September 13, PTC Therapeutics’ stock price closed at $47.33, which is ~0.66% growth from the close of $47.02 the previous day.

  • How Financially Strong Is PTC Therapeutics Inc (NASDAQ:PTCT)?
    Simply Wall St.7 days ago

    How Financially Strong Is PTC Therapeutics Inc (NASDAQ:PTCT)?

    Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as PTC Therapeutics Inc (NASDAQ:PTCT), with a market cap of US$2.38b, often getRead More...

  • PR Newswire7 days ago

    PTC Therapeutics to Participate at Upcoming Investor Conference

    SOUTH PLAINFIELD, N.J. , Sept. 13, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at Jefferies Gene Therapy Summit on Thursday, ...

  • PR Newswire13 days ago

    PTC Therapeutics Announces Winners of Global Duchenne Muscular Dystrophy Patient Group STRIVE Awards in Recognition of World Duchenne Awareness Day

    SOUTH PLAINFIELD, N.J., Sept. 7, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) is pleased to announce the recipients of the Company's 2018 global STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment) program, designed to support nonprofit organizations serving the Duchenne muscular dystrophy community. The impact of the STRIVE Awards will be felt across three different continents, with awards going to patient organizations in Argentina, Brazil, Canada, Croatia, Hungary, Ireland, Slovenia and Turkey.

  • ACCESSWIRE13 days ago

    Today's Research Reports on Trending Tickers: bluebird bio and PTC Therapeutics

    NEW YORK, NY / ACCESSWIRE / September 7, 2018 / U.S. benchmarks closed mostly lower on Thursday, with the Dow Jones remaining in the green, as internet and tech shares slumped. The Dow Jones Industrial ...

  • GlobeNewswire23 days ago

    New Research Coverage Highlights MACOM Technology Solutions, Arrowhead Pharmaceuticals, PTC Therapeutics, Boot Barn, Darling Ingredients, and Endologix — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MACOM ...

  • PR Newswire27 days ago

    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH PLAINFIELD, N.J., Aug. 24, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on August 22, 2018 it approved non-statutory stock options to purchase an aggregate of 381,500 shares of its common stock to 15 new employees.  The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on August 22, 2018 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

  • PR Newswire28 days ago

    PTC Therapeutics Successfully Completes Acquisition of Agilis Biotherapeutics

    SOUTH PLAINFIELD, N.J., Aug. 23, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT), today announced that it has successfully completed the acquisition of Agilis Biotherapeutics, Inc., a private biotechnology company focused on the advancement of innovative gene therapy programs for rare genetic disorders that affect the central nervous system (CNS). "We are excited to complete the acquisition and welcome the Agilis employees to PTC," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "We have added a team with exceptional gene therapy experience, a targeted micro-delivery gene therapy platform that has demonstrated durable clinical benefit, as well as gene therapy manufacturing and R&D capabilities.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Spark Therapeutics and PTC Therapeutics

    NEW YORK, NY / ACCESSWIRE / August 15, 2018 / U.S. equities snapped losses on Tuesday, as panic over Turkey’s currency eased and market participants focused on upbeat corporate earnings and strong economic ...

  • PR Newswirelast month

    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH PLAINFIELD, N.J., Aug. 10, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on August 6, 2018 it approved non-statutory stock options to purchase an aggregate of 170,200 shares of its common stock to 27 new employees.  The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on August 6, 2018 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

  • Ionis Pharmaceuticals (IONS) Q2 2018 Earnings Conference Call Transcript
    Motley Foollast month

    Ionis Pharmaceuticals (IONS) Q2 2018 Earnings Conference Call Transcript

    IONS earnings call for the period ending June 30, 2018.

  • PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates
    Zackslast month

    PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates

    PTC Therapeutics (PTCT) delivered earnings and revenue surprises of 75.00% and -1.56%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    PTC Therapeutics: 2Q Earnings Snapshot

    On a per-share basis, the South Plainfield, New Jersey-based company said it had a loss of 21 cents. Losses, adjusted for amortization costs, were 9 cents per share. The biopharmaceutical company posted ...

  • PR Newswirelast month

    PTC Therapeutics Reports Second Quarter 2018 Financial Results and Provides a Corporate Update

    Entered into agreement to acquire Agilis Biotherapeutics In-licensed LATAM commercial rights to Tegsedi™ (inotersen) and Waylivra™ (volanesorsen) EC approval of Translarna™ label expansion to children ...

  • ACCESSWIRElast month

    PTC Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / PTC Therapeutics, Inc. (NASDAQ: PTCT ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time. ...

  • PR Newswire2 months ago

    Akcea Therapeutics and PTC Therapeutics Collaborate to Commercialize Two Rare Disease Drugs in Latin America

    TEGSEDI has received marketing authorization approval from the European Commission (EC) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR amyloidosis). TEGSEDI is also the subject of a pending new drug application in the U.S. and Canada.

  • PR Newswire2 months ago

    PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2018 Financial Results

    SOUTH PLAINFIELD, N.J. , July 26, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2018 financial ...

  • Biogen Stock Trending Higher on Strong Q2 2018 Results
    Market Realist2 months ago

    Biogen Stock Trending Higher on Strong Q2 2018 Results

    Today, Biogen (BIIB) announced its earnings results for the second quarter of fiscal 2018. The company’s sales and earnings came in ahead of Wall Street estimates. Biogen’s spinal muscular atrophy drug, Spinraza, registered sales of $423 million in Q2 2018, which almost doubled compared to the $203 million sales reported in Q2 2017.

  • A Look at PTC Therapeutics’ Financial Position
    Market Realist2 months ago

    A Look at PTC Therapeutics’ Financial Position

    PTC Therapeutics (PTCT) generated revenues of $56.1 million in the first quarter, compared to $26.5 million in the first quarter of 2017. PTC Therapeutics’ Emflaza was launched in May 2017, which has driven the company’s revenue growth.

  • PTC Therapeutics to Acquire Agilis Biotherapeutics
    Market Realist2 months ago

    PTC Therapeutics to Acquire Agilis Biotherapeutics

    On July 19, PTC Therapeutics (PTCT) entered into an agreement to acquire Agilis Biotherapeutics. This acquisition is expected to include an upfront payment of $50.0 million in cash and ~$150.0 million in PTC Therapeutics common stock. The acquisition of Agilis Biotherapeutics by PTC Therapeutics is expected to close during the third quarter.

  • PR Newswire2 months ago

    PTC Therapeutics Announces Publication of Data Demonstrating the Clinical Differentiated Benefit of Deflazacort

    SOUTH PLAINFIELD, N.J., July 24, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced the publication of data in Muscle & Nerve comparing the efficacy and safety of deflazacort and prednisone/prednisolone from the placebo arm of the ACT DMD study.  The results demonstrated a clinically differentiated benefit of deflazacort over prednisone/prednisolone in slowing disease progression as measured using physical function endpoints and the time to delay loss of ambulation. Duchenne muscular dystrophy patients treated with deflazacort had notably less decline from baseline in 6-minute walk distance at Week 48 than those treated with prednisone/prednisolone.

  • PTC Therapeutics (PTCT) Soars: Stock Adds 9.4% in Session
    Zacks2 months ago

    PTC Therapeutics (PTCT) Soars: Stock Adds 9.4% in Session

    PTC Therapeutics (PTCT) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

  • What's Behind PTC Therapeutics' 10% Rally Today
    Motley Fool2 months ago

    What's Behind PTC Therapeutics' 10% Rally Today

    The company's making an acquisition to bulk up its pipeline of clinical-stage drugs.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: PTC Therapeutics and Seattle Genetics

    NEW YORK, NY / ACCESSWIRE / July 20, 2018 / U.S. indexes ended their five day winning streak, which was spurred by strong corporate earnings, as losses from the financial sector dragged markets lower on ...